1Fuhlendorff J, Rorsman p, Kofod H,et al. Stimulation of insulin release by repaglinide and glibenclamide involves both common and distinct processes[J]. Diabetes, 1998,47:345-351.
2WHO Dept. Of Noncommunicable Disease Surveillance[S]. Geneva, 1999.
3Grell W, Mark M, Luger P,et al. Repaglinide differs structurally from the sulphonylureas glibenclamide and glimepiride[J]. Diabetologia, 1997,40(Suppl 1):A321.
4Gromada J, Dissing S, Kofod H,et al. Effects of the hypoglycaemic drugs repaglinide and glibenclamide on ATP-sensitive potassium channels and cystosolic calcium levels in βTC3 cells and rat pancreaticβcells[J]. Diabetologia, 1995,38(9):1025-1032.
5Schwartz SL, Graf RJ, Polvino W, et al.Repaglinide in Type II diabetes: a placebo-controlled, doube-blind, randomized, dose-response study[C]. 1996, Novo Nordisk study AGEE/DED/064/USA: Data on file.
6Moses R, Slobodniuk R, Boyages S, et al. Additional treatment with repaglinide provides significant improvement in glycemic control in NIDDM patients poorly controlled on metformin[C]. 57th Scientific Sessions of the American Dabetes Association, Boston, MA, USA, 1997.
7Moses r, Slobodniuk R, Boyages S, et al. Effect of repaglinide addition to metformin monotherapy on glycemic control in patients with type 2 diabetes[J]. Diabetes Care, 1999,22:119-124.
8[5]Moses R,Slobodniuk R,Boyages S,et al.Additional treatment with repaglinide provides significant improvement in glycemic controling NIDDM patients poorly controlled on metformin[C].57th Scientific Sessions of the American Dabetes Association,Boston,MA,USA,1997.
9[6]Moses r,Slobodniuk R,Boyages S,et al.Effect of repaglinide addition to metformin monotherapy on glycemic control in patients with type 2 diabetes[J].DiabetesCare,1999,22:1192124.
